{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:28:01Z","timestamp":1765232881793,"version":"3.40.5"},"reference-count":19,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2020,11,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> In blood samples taken for testing purposes during drug infusion in the\nintensive care unit, there is a risk of interference due to drug-reactive interaction during the\nanalysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case Report:<\/jats:title>\n<jats:p> A 19-year-old female patient had undergone surgery for intracranial astrocytoma, 12\nyears ago. Acinetobacter baumannii was found in the blood culture and deep tracheal aspiration\nfluid of the patient who had a fever (39.2 \u00b0C) with a body temperature during the follow-up. The\npatient was started on colistin 2 * 4.5 million IU. After the colistin infusion, biochemical tests were\nrequested to control the patient\u2019s clinical situation. CK-MB mass and ProBNP values were\nmeasured in high concentrations. Cardiology consultation was requested to evaluate the increase\nin the CK-MB mass and ProBNP values. The patient's ECG and echocardiography showed no\nabnormality. The increase in cardiac markers was neither clinically acceptable nor insignificant.\nThere was no hemolysis in the sample or analytical error in the device. Variability in the tests was\nthought to be due to the interference. As the bloodletting time was questioned, it was determined\nthat it was taken during colistin treatment. In order to determine the effect of colistin-related\ninterference on the other tests, the laboratory was contacted and additional tests (TSH, FT4, Anti-\nTPO, B-HCG, Estradiol, Prolactin, CA 125, CA 15-3, CA 19-9, Vitamin B12, C-Peptide, DDimer,\nPTH, 25 hydroxy vitamin D, PT, INR, APTT) were conducted. During colistin treatment,\nin many tests, bias was detected between -75 and + 268.80%.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Clinicians should consider suspicious test results that are incompatible with the\ndiagnosis for the possibility of erroneous measurements due to colistin interference and review the\nsampling processes.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1386207323666200514072705","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T16:43:21Z","timestamp":1589474601000},"page":"827-831","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["False Laboratory Test Result Through Colistin Interference in an Intensive Care Patient: Case Report"],"prefix":"10.2174","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5661-4499","authenticated-orcid":true,"given":"Veli F.","family":"Pehlivan","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Reanimation, Harran University Faculty of Medicine, Sanliurfa, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7200-1537","authenticated-orcid":true,"given":"Ataman","family":"G\u00f6nel","sequence":"additional","affiliation":[{"name":"Department of Medicinal Biochemistry, Harran University Faculty of Medicine, Sanliurfa, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6985-343X","authenticated-orcid":true,"given":"Basak","family":"Pehlivan","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Reanimation, Harran University Faculty of Medicine, Sanliurfa, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9469-4757","authenticated-orcid":true,"given":"Ismail","family":"Koyuncu","sequence":"additional","affiliation":[{"name":"Department of Medicinal Biochemistry, Harran University Faculty of Medicine, Sanliurfa, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s11096-017-0520-9","volume":"39","author":"Dookeeram D.","year":"2017","unstructured":"Dookeeram D.; Bidaisee S.; Paul J.F.; Nunes P.; Robertson P.; Maharaj V.R.; Sammy I.; Polypharmacy and potential drug-drug interactions in emergency department patients in the Caribbean. Int J Clin Pharm 2017,39(5),1119-1127","journal-title":"Int J Clin Pharm"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.2042-7174.2012.00221.x","volume":"20","author":"Smithburger P.L.","year":"2012","unstructured":"Smithburger P.L.; Kane-Gill S.L.; Seybert A.L.; Drug-drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved. Int J Pharm Pract 2012,20(6),402-408","journal-title":"Int J Pharm Pract"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcrc.2017.08.021","volume":"43","author":"Jankovi\u0107 S.M.","year":"2018","unstructured":"Jankovi\u0107 S.M.; Pej\u010di\u0107 A.V.; Milosavljevi\u0107 M.N.; Opan\u010dina V.D.; Pe\u0161i\u0107 N.V.; Nedeljkovi\u0107 T.T.; Babi\u0107 G.M.; Risk factors for potential drug-drug interactions in intensive care unit patients. J Crit Care 2018,43,1-6","journal-title":"J Crit Care"},{"key":"ref=4","author":"Garza D.","year":"2012","unstructured":"Garza D.; Becan-McBride K.;  Phlebotomy Handbook 2012","journal-title":"Phlebotomy Handbook"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/cvr\/cvz277","volume":"115","author":"Vroemen W.H.M.","year":"2019","unstructured":"Vroemen W.H.M.; van Doorn W.P.T.M.; Kimenai D.M.; Wodzig W.K.W.H.; de Boer D.; Bekers O.; Meex S.J.R.; Biotin interference in high-sensitivity cardiac troponin T testing: a real-world evaluation in acute cardiac care. Cardiovasc Res 2019,115(14),1950-1951","journal-title":"Cardiovasc Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/B978-0-12-813776-5.00008-X","author":"Trambas C.","year":"2019","unstructured":"Trambas C.;  In Accurate Results in the Clinical Laboratory 2019,83-97","journal-title":"In Accurate Results in the Clinical Laboratory"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1086\/429323","volume":"40","author":"Falagas M.E.","year":"2005","unstructured":"Falagas M.E.; Kasiakou S.K.; Saravolatz L.D.; Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005,40(9),1333-1341","journal-title":"Clin Infect Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1128\/AAC.49.8.3136-3146.2005","volume":"49","author":"Kasiakou S.K.","year":"2005","unstructured":"Kasiakou S.K.; Michalopoulos A.; Soteriades E.S.; Samonis G.; Sermaides G.J.; Falagas M.E.; Combination therapy with intravenous colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005,49(8),3136-3146","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"8301","DOI":"10.1007\/s00253-019-10028-5","volume":"103","author":"Rahbarnia L.","year":"2019","unstructured":"Rahbarnia L.; Farajnia S.; Naghili B.; Ahmadzadeh V.; Veisi K.; Baghban R.; Toraby S.; Current trends in targeted therapy for drug-resistant infections. Appl Microbiol Biotechnol 2019,103(20),8301-8314","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/FTD.0b013e31825c827a","volume":"34","author":"Thomas T.A.","year":"2012","unstructured":"Thomas T.A.; Broun E.C.; Abildskov K.M.; Kubin C.J.; Horan J.; Yin M.T.; Cremers S.; High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma. Ther Drug Monit 2012,34(4),398-405","journal-title":"Ther Drug Monit"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1592\/phco.30.12.1279","volume":"30","author":"Lim L.M.","year":"2010","unstructured":"Lim L.M.; Ly N.; Anderson D.; Yang J.C.; Macander L.; Jarkowski A.; Forrest A.; Bulitta J.B.; Tsuji B.T.; Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010,30(12),1279-1291","journal-title":"Pharmacotherapy"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1128\/AAC.45.3.781-785.2001","volume":"45","author":"Li J.","year":"2001","unstructured":"Li J.; Turnidge J.; Milne R.; Nation R.L.; Coulthard K.; In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001,45(3),781-785","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3109\/00365513.2016.1143113","volume":"76","author":"Mongolu S.","year":"2016","unstructured":"Mongolu S.; Armston A.E.; Mozley E.; Nasruddin A.; Heterophilic antibody interference affecting multiple hormone assays: Is it due to rheumatoid factor? Scand J Clin Lab Invest 2016,76(3),240-242","journal-title":"Scand J Clin Lab Invest"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.clinbiochem.2017.08.015","volume":"50","author":"Ward G.","year":"2017","unstructured":"Ward G.; Simpson A.; Boscato L.; Hickman P.E.; The investigation of interferences in immunoassay. Clin Biochem 2017,50(18),1306-1311","journal-title":"Clin Biochem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ijantimicag.2009.10.005","volume":"35","author":"Falagas M.E.","year":"2010","unstructured":"Falagas M.E.; Rafailidis P.I.; Ioannidou E.; Alexiou V.G.; Matthaiou D.K.; Karageorgopoulos D.E.; Kapaskelis A.; Nikita D.; Michalopoulos A.; Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010,35(2),194-199","journal-title":"Int J Antimicrob Agents"},{"key":"ref=16","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-210787","volume":"2015","author":"Nigam A.","year":"2015","unstructured":"Nigam A.; Kumari A.; Jain R.; Batra S.; Colistin neurotoxicity: revisited. BMJ Case Rep 2015,2015","journal-title":"BMJ Case Rep"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2174\/1386207322666190722155106","volume":"22","author":"Gonel A.","year":"2019","unstructured":"Gonel A.; Yetisgin A.; False negative d vitamin measurement in LC-MS\/MS method due to hyperlipidemia: case report. Comb Chem High Throughput Screen 2019,22(6),428-430","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=18","author":"Rodziewicz T.L.","year":"2019","unstructured":"Rodziewicz T.L.; Hipskind J.E.;  Medical Error Prevention 2019","journal-title":"Medical Error Prevention"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2174\/1386207322666190603170438","volume":"22","author":"Tascanov M.B.","year":"2019","unstructured":"Tascanov M.B.; G\u00f6nel A.; How do contrast agents affect cardiac markers and coagulation tests? experimental study. Comb Chem High Throughput Screen 2019,22(5),355-360","journal-title":"Comb Chem High Throughput Screen"}],"container-title":["Combinatorial Chemistry &amp; High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/181929","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/181929\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/181929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T13:54:57Z","timestamp":1621605297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/181929\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,11,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1386207323666200514072705","relation":{},"ISSN":["1386-2073"],"issn-type":[{"type":"print","value":"1386-2073"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}